Crossmark

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Crossref DOI link: https://doi.org/10.1186/s40425-019-0669-y

Published Online: 2019-07-19

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hurkmans, Daan P. https://orcid.org/0000-0002-8750-5188
Basak, Edwin A.

van Dijk, Tanja

Mercieca, Darlene

Schreurs, Marco W. J.

Wijkhuijs, Annemarie J. M.

Bins, Sander

Hoop, Esther Oomen-de

Debets, Reno

Joerger, Markus

Odink, Arlette

van der Veldt, Astrid A. M.

van der Leest, Cor H.

Aerts, Joachim G. J. V.

Mathijssen, Ron H. J.

Koolen, Stijn L. W.
License Information

Text and Data Mining valid from 2019-07-19
More Information

Article History

Received: 27 May 2019

Accepted: 8 July 2019

First Online: 19 July 2019

Ethics approval and consent to participate

: Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16–011), patients signed written informed consent provided before study entry.

: Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16–011), patient signed written informed consent provided before study entry.

: AV and JA have a consulting and advisory role at BMS. All remaining authors declare no potential conflicts of interest.